ABVC BioPharma (ABVC) Competitors $0.55 -0.02 (-3.07%) (As of 11:03 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ABVC vs. BLRX, INKT, DARE, PLUR, RNXT, NAII, TNXP, MRKR, DRRX, and LGVNShould you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include BioLineRx (BLRX), MiNK Therapeutics (INKT), Daré Bioscience (DARE), Pluri (PLUR), RenovoRx (RNXT), Natural Alternatives International (NAII), Tonix Pharmaceuticals (TNXP), Marker Therapeutics (MRKR), DURECT (DRRX), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry. ABVC BioPharma vs. BioLineRx MiNK Therapeutics Daré Bioscience Pluri RenovoRx Natural Alternatives International Tonix Pharmaceuticals Marker Therapeutics DURECT Longeveron BioLineRx (NASDAQ:BLRX) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability. Is BLRX or ABVC more profitable? BioLineRx has a net margin of 0.00% compared to ABVC BioPharma's net margin of -1,619.65%. ABVC BioPharma's return on equity of -104.94% beat BioLineRx's return on equity.Company Net Margins Return on Equity Return on Assets BioLineRxN/A -225.62% -51.71% ABVC BioPharma -1,619.65%-104.94%-56.81% Does the media prefer BLRX or ABVC? In the previous week, BioLineRx had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for BioLineRx and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.73 beat BioLineRx's score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ABVC BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend BLRX or ABVC? BioLineRx presently has a consensus target price of $21.00, indicating a potential upside of 5,779.06%. Given BioLineRx's stronger consensus rating and higher possible upside, equities research analysts clearly believe BioLineRx is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer BLRX or ABVC? BioLineRx received 505 more outperform votes than ABVC BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformBioLineRxOutperform Votes50572.77% Underperform Votes18927.23% ABVC BioPharmaN/AN/A Which has more risk & volatility, BLRX or ABVC? BioLineRx has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Do institutionals and insiders hold more shares of BLRX or ABVC? 1.6% of BioLineRx shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 11.9% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, BLRX or ABVC? ABVC BioPharma has lower revenue, but higher earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLineRx$4.80M5.95-$60.61M-$0.45-0.79ABVC BioPharma$150K47.59-$10.52M-$0.86-0.64 SummaryBioLineRx beats ABVC BioPharma on 10 of the 17 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVC vs. The Competition Export to ExcelMetricABVC BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.14M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E Ratio-0.644.9791.2813.60Price / Sales47.59371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book0.9010.306.906.33Net Income-$10.52M$153.61M$118.83M$225.93M7 Day Performance-0.18%-1.73%-1.92%-0.96%1 Month Performance1.85%-7.26%-3.75%1.06%1 Year Performance-69.10%31.10%31.37%26.59% ABVC BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVCABVC BioPharma0.751 of 5 stars$0.55-3.1%N/A-66.4%$7.14M$150,000.00-0.6430Gap UpBLRXBioLineRx1.9751 of 5 stars$0.36-34.5%$21.00+5,779.1%-67.9%$28.56M$4.80M0.0040News CoverageGap DownHigh Trading VolumeINKTMiNK Therapeutics3.2235 of 5 stars$0.70-0.7%$6.50+828.6%-34.1%$27.69MN/A-1.8130Analyst RevisionGap DownDAREDaré Bioscience2.203 of 5 stars$3.18flat$24.00+654.7%-23.9%$27.67M$2.81M-5.3830PLURPluri0.1524 of 5 stars$4.96-2.0%N/A+11.5%$27.58M$330,000.000.00150RNXTRenovoRx2.6223 of 5 stars$1.13-5.0%$6.13+442.0%+98.7%$27.12MN/A-2.126News CoveragePositive NewsNAIINatural Alternatives International0.3468 of 5 stars$4.36-1.4%N/A-27.8%$27.03M$113.80M0.00290Analyst ForecastNews CoverageTNXPTonix Pharmaceuticals2.9424 of 5 stars$0.20+3.1%$53.50+27,209.9%-98.8%$26.89M$7.77M0.00103Analyst ForecastGap DownMRKRMarker Therapeutics3.8639 of 5 stars$3.01-5.3%$19.00+531.2%+17.8%$26.85M$3.31M0.0060DRRXDURECT3.0843 of 5 stars$0.86-4.8%$5.00+481.3%+39.5%$26.70M$8.55M0.0080Analyst ForecastAnalyst RevisionNews CoverageGap DownLGVNLongeveron2.3938 of 5 stars$1.85+0.0%$8.00+332.3%-90.4%$26.57M$710,000.000.0023 Related Companies and Tools Related Companies BioLineRx Competitors MiNK Therapeutics Competitors Daré Bioscience Competitors Pluri Competitors RenovoRx Competitors Natural Alternatives International Competitors Tonix Pharmaceuticals Competitors Marker Therapeutics Competitors DURECT Competitors Longeveron Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABVC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
